Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.58 |
| ▸ | ACHE | P22303 | 5/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12090230 | 1.00 | BCHE (0.58) | BCHEACHEMAOBPOLBMEN1 | |
| SCHEMBL4917481 | 0.92 | DRD2 (0.52) | BCHEACHEMAOBALDH1A1 | |
| SCHEMBL2576650 | 0.92 | DRD2 (0.52) | BCHEACHEMAOBALDH1A1 | |
| SCHEMBL4917475 | 0.92 | DRD2 (0.52) | BCHEACHEMAOBALDH1A1 | |
| SCHEMBL9208266 | 0.87 | BCHE (0.58) | BCHEACHEMAOBPOLBMEN1 | |
| SCHEMBL5765604 | 0.85 | ALDH1A1 (0.53) | BCHEACHEMAOBALDH1A1 | |
| SCHEMBL1943416 | 0.84 | ACHE (0.53) | BCHEACHEMAOBPOLBMEN1 | |
| SCHEMBL5745231 | 0.82 | BCHE (0.58) | BCHEACHEMAOBCYP2D6ALDH1A1 | |
| SCHEMBL28497475 | 0.82 | BCHE (0.58) | BCHEACHEMAOBCYP2D6ALDH1A1 | |
| SCHEMBL19209909 | 0.82 | BCHE (0.58) | BCHEACHEMAOBCYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168071-B2 | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200299268-A1 | SMALL MOLECULE INHIBITORS OF SHARED EPITOPE-CALRETICULIN INTERACTIONS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2020-09-24 | — | — | US | disclosed |
| US-10723718-B2 | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190135783-A1 | SMALL MOLECULE INHIBITORS OF SHARED EPITOPE-CALRETICULIN INTERACTIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-09 | — | — | US | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723718-B2 | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use | CALR, PTPRC, PTPRJ | BCHE 3103/4885ACHE 4412/4885MAOB 4861/4885 |
| US-11168071-B2 | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use | CALR, PTPRC, PTPRJ | BCHE 3126/4885ACHE 4404/4885MAOB 4861/4885 |
| US-20190135783-A1 | SMALL MOLECULE INHIBITORS OF SHARED EPITOPE-CALRETICULIN INTERACTIONS AND METHODS OF USE | CALR, PTPRC, PTPRJ | BCHE 3126/4885ACHE 4404/4885MAOB 4861/4885 |
| US-20200299268-A1 | SMALL MOLECULE INHIBITORS OF SHARED EPITOPE-CALRETICULIN INTERACTIONS AND METHODS OF USE | CALR, PTPRC, PTPRJ | BCHE 3126/4885ACHE 4404/4885MAOB 4861/4885 |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | JAK3, JAK1, UACA | BCHE 3151/4885ACHE 4643/4885MAOB 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.